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1. Introduction 
China is situated in the south-eastern part of the Eurasian continent and has a total land area 
of 9.6 million square kilometers. It is composed of 23 provinces, five autonomous regions 
(Inner Mongolia, Ningxia Hui, Guangxi Zhuang, Xinjiang Weiwuer, and Tibet), four 
municipalities directly under the central authorities (Beijing, Shanghai, Tianjin and 
Chongqing), and two Special Administrative Region(SAR)(Hong Kong and Macao). China is 
a unified, multinational country (56 nationalities), with a population of about 1.37billion, of 
which 1.34 billion live in mainland. According to a survey carried out in 1987, the birth 
defects were of 4% in China. It is a big burden for the population. The government has paid 
attention to this situation. In order to improve the public health, China government passed 
the “Maternal and Child Health Law” in 1994.  
Prenatal diagnosis for severe birth defects was implemented in China step by steps. 
2. The outlines of the development of prenatal diagnosis in China 
2.1 Prenatal diagnosis of central neural tube defects 
The earliest cases of prenatal diagnosis for central neural tube defects (NTD) were 
performed with measuring the level of alpa-fetal protein in maternal serum in 1976. This 
work was awarded by the MOH of China and WHO. Ultrasoundnography was used to 
diagnose NTD routinely after 1980’. 
2.2 Karyotyping 
Fetal chromosome karyotyping was performed in 1970’ on cultured amnion fluid cells to 
detect chromosomal diseases[1,2]. It became the major technique used for prenatal diagnosis 
in China in 1980’. The scale was once declined in the 1990’. After the prenatal diagnosis 
spreed in China, cytogenetics is the main field for prevention of hereditary diseases.  
2.3 Fetoscopy  
Usage of fetoscopy was reported in the late of 1980’. It was used for biopsy of the fetal 
material and for fetal therapy[3,4].  
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2.4 Maternal serum screening  
Maternal serum screening for chromosomal abnormalities and other abnormalities, such as 
NTD, started in the early of 1990’[5]. This procedure was adopted nationwide in the 21 
century. A standard operation protocol was formulated in 2010 by the National Committee 
of Exports on Prenatal Diagnosis.  
2.5 Biochemical genetics 
Electrophoresis analysis was perform on amnion fluid as the first technique in prenatal 
diagnosis of metabolic disease[6,7]. After the enzyme assay methods were established, 
prenatal diagnosis of lysosomal diseases was carried out by enzyme assay[8]. More than 20 
protocols were developed for diagnosis of lysosomal storage diseases.  
2.6 Techniques developed for sampling fetus material 
2.6.1 Amniocentesis  
Amniocentesis was the first procedure for fetal cell sampling. It was performed as early as in 
1970 in China. It became the major procedure in collection fetal material nationwide now. 
2.6.2 Chorionic villus sampling (CVS)  
At the early stage, chorionic villus sampling via the cervix under was invented by a Chinese 
obstetrician[9]. Transcervical chorionic villus sampling(TC-CVS) was reintroduced into 
China in the early of 1980’ and got popular afterward. It was performed blindly at the very 
beginning, e.g. without the guidance of ultrasonography as does later, for prenatal diagnosis 
at early pregnancy(first trimester)[10]. It was further improved. Transabdominal chorionic 
vilus sampling(TA-CVS) was established in 1994[11]. 
2.6.3 Fetal blood sampling 
Fetal blood sampling via abdominal cordocentesis was performed in the late 1980’ for cell 
culture or hemoglobin analysis[12]. It is used rather routinely in the area where there is a 
high prevalence of hemoglobinopathies, since the blood component can be analyzed with 
the fetal blood.  
2.7 Gene diagnosis 
The first prenatal gene diagnosis was performed in the early of 1980’ on thalassemia[30]. 
Then prenatal diagnosis was performed on more and more monogenic diseases, when the 
gene mutations had been characterized for the disease, such as DMD, PKU, and hemophilia 
A (see details in section 3). 
2.8 Regulations on prenatal diagnosis 
As the prenatal diagnosis was offered nationwide, there were more and more problems 
emerged. It was necessary to make a regulation on the practices of prenatal diagnosis. In the 
second national conference of prenatal diagnosis 2000, this issue was discussed and a 
proposal on the regulation for prenatal diagnosis was sent to the Ministry of Public Health 
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after the meeting. A special group was organized to investigate the demands on prenatal 
diagnosis and the diseases needed to be put on the list for prenatal diagnosis. In the third 
national conference of prenatal diagnosis 2001, the draft of the regulation was discussed. 
After revising, “the regulations on prenatal diagnosis and diagnosis of genetic diseases” was 
distributed nationwide for further discussion and for modification. After one year debating, 
“The Regulation on Management of Techniques for Prenatal Diagnosis” was published on 
Dec. 22, 2002 and was implemented after May 1, 2003 [http://www.china.com.cn/policy/ 
txt/2003-02/14/content_5276708.htm]. A National Committee of Exports on Prenatal 
Diagnosis was established in 2004 to assist the work of the Division of Women’s Health and 
Community Health Care, MOH in prenatal diagnosis. 
2.9 The current situation of the organizations for prenatal diagnosis 
The techniques applied in the practices of prenatal diagnosis are cytogenetics, maternal 
serum screening, and ultrasounography. The prenatal diagnosis centers were assigned by 
the authorities in charge of public health of the local government. Up to year 2009, there 
were 511 centers carrying out maternal serum screening for chromosomal diseases and 
neural tube defects; 169 centers performing karyotyping for pregnancy at high risk or with a 
positive result of serum screening, and ultrasoundography for malformations.  
A total of 93905 prenatal diagnoses were carried out for chromosomal diseases and 
monogenic diseases in 2009. Fetal sampling was mainly carried out via amniocentesis (80%), 
only a small section was by CVS (1.8%). 
There were only 76 centers offering gene diagnosis, of which the most were located in the 
developed areas, such as Beijing , Shanghai, Hunan, Henan, Guangdong, and Guangxi.  
Nineteen diseases were carried out in some of the prenatal diagnosis centers, most of which 
were ǂ-thalssemia, ǃ-thalassemia, DMD, PKU, SMA, achondroplasia, APKD, and hereditary 
non-syndromic deafness. 
3. Prenatal gene diagnosis, the strategies and experiences in several 
common diseases 
3.1 Thalassemias 
Thalassemia is one of the most common monogenic disorders in the world. The incidence 
for this disease is high in tropical and subtropical areas including southern China. 
In China, the carrier rate of ǂ-thalassemia was 17.55% in Guangxi, 8.53% in Guangdong and 
1% to 4.2% in other province of southern China[13,14]. The frequencies of ǂ-thalassemic 
allele in Li Monority was 0.347. Fortunately, most of the thalassemic alleles were ǂ-thal-2 (-
ǂ3.7/ or -ǂ4.2/) , only 0.0058 for ǂ-thal-1 allele (--SEA/)[15]. The estimated incidence of carriers 
of ǃ-thalassemia is as high as 6.43% in Guangxi, and 1% to 2.54% in populations in the 
endemic areas of southern China[13,16]. 
3.1.1 Mutation characterization 
Researches on thalassemias started in the early of 1980’s in China.  
The organization of the ǂ globin was analyzed with Southern blotting. Data collected in 
Guangxi showed the defects of ǂ globin genes in ǂ-thalassemia patients were mostly 
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deletion types, --SEA/,-ǂ3. 7/, and -ǂ4. 2/.[17] Three primers bridging the deletion breakpoints 
were designed to detect these three deletion mutations [18]. Abnormal hemoglobins of the ǂ 
globin gene, HbǂCS and HbǂQS, were characterized as thalassemic mutation. After 
sequencing the non-deletion ǂ thalassemic mutant HBA, 12 mutations were revealed 
responsible for ǂ-thalassemia[http://globin.cse.psu.edu ]. Reverse dot blotting with ASO 
probes (RDB) for ǂCD30(-GAG), ǂCD31(G>A), ǂCD59(G>A), ǂWestmead (CD22, C>G), ǂQS(CD125, 
T>C) and ǂCS (CD142, T>C) were developed in detection of the non-deletion ǂ-thalassemia 
alleles. [19]  
The mutations causing ǃ-thalassemia were exclusively point mutations[20]. It used to be 
the strategy to use the RFLP haplotype to predict mutations since there was linkage 
disequilibrium between the haplotypes and certain mutations [21]. The -29 A>G mutation 
was revealed as it was associated with a new haplotype. The mutations were identified 
via cloning and sequencing, the routine procedure for identifying mutations at that time. 
It was the first mutation of ǃ-thalassemia characterized by the scientist from mainland 
China on patients collected in Guangzhou, Guagndong Province[22]. In the 1990’, most of 
the mutations were characterized with direct sequencing the PCR products. Five 
mutations, CD41-42 (-CTTT), IVS2-654 (C>T), –28 (A>G), CD26 (G>A) and CD17 (A>T), 
account for 90% of the common mutations in south China. New mutation was revealed 
with the RDB and characterized by direct sequencing. To date, 46 single-nucleotide 
mutations and small deletions in HBB have been characterized in the Chinese patients 
with ǃ-thalassemia [http://globin.cse.psu.edu]. The recently developed technique is the 
probe-based melting curve analysis (MeltPro HBB assay). It is a qualitative in vitro 
diagnostic method designed to genotype a panel of 24 single-nuclueotide mutations and 
small indels in the HBB gene that cause ǃ-thalassemia or abnormal hemoglobin. The test 
kit is based on a proprietary, multicolored, self-quenched, probe-based melting curve 
analysis performed with a standard real-time PCR instrument, from which genotype 
information for each mutation is retrieved based on the melting temperature (Tm) or 
difference in Tm between wild-type and mutant DNA samples[16].  
3.1.2 The strategy in thalassemia prevention 
In the report on the middle term evaluation on the progress of the National Project on 
thalassemia during the Seventh Five-Year Developing Plan in 1988, Shangzhi Huang had 
made a proposal on performing a population prevention program on thalassemia by 
hematological screening, mutation detection, and prenatal gene diagnosis in certain areas. 
The trail of population screening carriers with thalassemias was carried out on the Li 
Minority in Hainan in 1990. It showed that it was feasible to screening thalassemias with 
hematological parameters [23]. In the Li Minority in Hainan the carrier rate of ǃ-thalassemia 
was 8.6%, and the mutation c.124-127delTTCT accounted for 94.7% of the mutant alleles in 
this population [24]. In 1991, carrier screening for thalassemias was carried out for people in 
marriage registration in Fushan City, Guangdong Province [25]. In 1993, Xiangmin Xu et al. 
started the hospital-based screening program for pregnant women during their first prenatal 
checking up in Guangdong and Guangxi [26].  
In hematological screening, quantitative test of hemoglobin, erythrocyte osmotic fragility, 
mean corpuscular volume (MCV), and hemoglobin electrophoresis were performed. When 
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erythrocyte osmotic fragility <60%, MCH<27pg, and MCV <80 fl, hemoglobin 
electrophoresis was carried out on the positive subjects. When HbA2≥3.5% or HbA2 normal 
but HbF >3%, ǃ-thalassemia was suspected, while if HbA2<3.5%, ǂ-thalassemia would 
considered. Iron deficiency anemia should be ruled out with serum iron test. The DNA were 
isolated later and Gap-PCR[27] and RDB[28] methods were used for ǂ-thalassemia 
genotyping. ǃ-thalassemia genotyping were carried out using RDB analysis for 18 common 
types of point mutation[29]. In the RDB procedure two-step hybridization was designed: the 
first dot strip contained ASO probes specific for seven common mutations, e.g., -28A>G, 
CD17A>T, CD26G>A, IVS1 nt5G>C, CD41/42 del CTTT, CD71/72 +A, IVS2 nt654C>T, and 
IVS2 nt652C>T; the second dot strip contained 11 less common but not rare mutations in 
Chinese, e.g.,-32C>A. -30T>C, -29A>G, +40_43 del AAAC, initial CD ATG>ACG, 
CD14/15+G, CD27/28+C, IVS1 nt1G>T, CD31-C, CD43G>T, and CD71/72+T [29]. DNA 
sequencing was also performed if there was an unknown allele of no-deletion ǂ mutation 
remained. Four common types of ǂ-thalassemia mutations, -ǂ3. 7/, -ǂ4. 2/, --SEA/, and ǂCSǂ/ 
alleles, were tested for all the subjects with ǃ-thalassemia trait to reveal possible situation of 
ǃ/ǂ-thalassemia double heterozygote [26]. If the woman was identified as a heterzygote of 
thalassemia, her spouse would be tested for the same type thalassemia. If the couple were 
both heterozygous for the same type of thalassemias, either ǃ- or ǂ-thalassemia, prenatal 
diagnosis will be suggested to the couple. 
3.1.3 Prenatal diagnosis 
Thalassemia is a severe disease, and its treatment requires life-long transfusion and iron 
chelating. While many cities in China have facilities for diagnosis and treatment of this 
disease, free medical services are not provided by the government in most rural areas. 
Treatment is available to only a potion of patients who can afford it, although this situation 
is more favorable in some regions with better economical development. So, there is still a 
demand for prenatal diagnosis of thalassemia. 
Prenatal gene diagnosis on ǂ-thalassemia was carried out in the early stage by Southern 
blotting [30] or with a simple but not accurate method, dot blot hybridization with ǂ globin 
probe[31]. When polymerase chain reaction (PCR) was established, gap-PCR became a 
major approach in prenatal diagnosis of ǂ-thalassemia to detect the deletion mutation on 
fetus [32], or RDB was used to detect the point mutation of ǂ-thalassemia [28].  
Haplotypes of the RFLP sites on the ǃ-globin cluster were used for linkage analysis in the 
early stage for diagnosis of ǃ-thalassemia. Prenatal diagnosis was mainly performed with 
ASO probes routinely now, also there were several modifications being made, such as 
labeled with non-radioactive material, RDB, primer extension, and probe-based melting 
curve analysis (MeltPro HBB assay) [16].  
The first prenatal diagnosis of ǃ-thalassemia was carried out in 1985 with RFLP linkage 
analysis[33,34]. It was PCR technique that overcame the obstacle of the limited amount 
DNA from fetus available for RFLP analysis. Using PCR technique combined with the 
radioactive labeled allele specific oligonucleotide (ASO) probes, prenatal gene diagnosis for 
ǃ-thalassemia become much easier, not only for less DNA was used but also for its simple 
and quick performance [35] . The non-radioactive labeling ASO probes and RDB made the 
prenatal diagnosis procedure even easier. This new techniques has been the routine 
approach for prenatal diagnosis of ǃ thalassemia in China[36].  
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There were other techniques used in China for prenatal diagnosis, such as allele specific 
PCR(AS-PCR)[37], multiplex AS-PCR[38]. Another approach is RFLP analysis by 
introducing an artificial base substitution to create restriction sites. PCR products were cut 
by certain restrictive enzyme and then visualized the fragments after electrophoresis in 
agarose gel [39].  
3.2 Duchenne muscular dystrophy (DMD) 
3.2.1 Clinical aspect 
Duchenne and Becker muscular dystrophy (DMD/BMD) (MIM#300377 and 300376) are 
allelic disorders, caused by mutations in the DMD gene coding for dystrophin, which 
locates on Xp21. The term "pseudohypertrophic muscular dystrophy" was used in the past; 
however, it is not used currently because pseudohypertrophy is not unique to the DMD or 
BMD phenotype. DMD is the severe form and usually presents in early childhood with 
develop delayed, including delays in sitting and standing independently. Progressive 
symmetrical muscular weakness, proximal severer than distal, before age 5 years, with a 
waddling gait and difficulty climbing, often with calf hypertrophy. Serum creatine 
phosphokinase (CK) concentration elevated, generally 10 times the normal range. 
Electromyography (EMG) is useful in distinguishing a myopathic disease from a neurogenic 
disorder. The characteristics were demonstrating short-duration, low-amplitude, 
polyphasic, rapidly recruited motor unit potentials. Muscle histology early in the disease 
shows nonspecific dystrophic changes, including variation in fiber size, foci of necrosis and 
regeneration, hyalinization, and, later in the disease, deposition of fat and connective tissue. 
Immunohistochemistry with antibody against dystrophin showed no signal of the 
dystrophin. Western blot can be used to distinguish DMD from other muscular dystrophies, 
such as Limb-girdle muscular dystrophy (LGMD), which are clinically similar to DMD but 
were autosomal recessive or autosomal dominant inheritance. LGMDs are caused by 
mutations in genes that encode sarcoglycans and other proteins associated with the muscle 
cell membrane that interact with dystrophin [40]. Testing for deficiency of proteins from the 
transmembrane sarcoglycans complex is indicated in individuals with dystrophin-positive 
dystrophies. 
The affected children will loss their walking ability by age 12 years old. Few patients survive 
beyond the third decade, with respiratory complications and cardiomyopathy, which are the 
common causes of death. BMD is the mild form characterized by later-onset skeletal muscle 
weakness. Individuals with BMD remain ambulatory into their 20s and the lifespan is 
longer. Female carriers have clinical features of DMD were resulted in the situations either 
of X-Auto-chromosome crossing over involving DMD locus, or because of Turner syndrome 
or non-random X-chromosome inactivation (XCI), so called “unfortunate Lyonization”. 
3.2.2 Mutation analysis 
The size of DMD gene is over 2.3 Mb, and composes 79 exons. It is the largest known human 
gene. The cDNA is 14kb. Large fragment deletion or duplication were the most common 
mutations of DMD, 60% for deletion and 6% for duplication with some were indel type, e.g., 
deletion with addition of several base pairs at the same site. There were cases with two 
deletions or deletion plus duplication scattered in the same allele[41-43]. There are two 
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hotspots of deletion/duplication, one located on the 5’ portion, harboring exons 2 to 20, the 
other in the 3’ portion involving exons 44 to 53. The remaining mutations were small 
deletion, insertion, point mutations and splicing mutations. 
There were several methods for deletion/duplication analysis. In the early stage, Southern 
blotting was used with either genomic probes or cDNA probes, both deletion and 
duplication mutations were detectable[44]. With multiplex PCR approximately 98% of 
deletions are detectable[45,46]. Multiplex ligation-dependent probes assay (MLPA) has been 
employed for deletion/duplication analysis of the DMD gene in probands and for carrier 
detection in recent years[42,43]. 
Array chips for deletion or duplication mutations were also developed, it had the same 
power in detection of large deletion/duplication as MLPA, but the strength on detection of 
alterations with small size is under evaluation[47].  
Mutation scanning with denaturing high performance liquid chromatography (DHPLC) or 
high resolution melting assay (HRM) followed by direct sequence analysis was performed, 
but the efficiency is low [48]. It might be a good choice to perform RT-PCR and then 
sequencing. It would much easier to detect the size changes of the mRNA just by agarose gel 
electrophoresis, which were caused by large deletion/duplication or splicing abnormalities. 
If there is no or reduced RT-PCR products, mutations occurred on the regulatory elements 
would be suspected and sequence analysis would be performed then using genomic DNA 
to detect the sequence change. It also facilitates detection of the point mutations since the 
size of cDNA is much shorter than the genomic DNA.  
A “one-step approach” was developed with multiplex PCR using 9 primer pairs to detect 
deletions and to perform linkage analysis simultaneously[49]. The primers amplified 3 
exons, exon 8, 17 and 19, in the 5’ hotsport[50], and 6 short tandem repeats, 5’CA at the brain 
specific promoter region [51]and MP1P[52] at 3’UTR, and STR markers in introns 44, 45, 49 
and 50[53]. The primers were grouped into three triplex PCR, Group A: 5’CA, MP1P and 
exon 8; Group B: exon 17, i44 and i49; Group C: exon 19, i45 and i50. The amplified 
fragments in the group can also serve as the internal control, since deletion is rarely spread 
all the gene, although one deletion gene had been detected, of which only one fragment was 
amplified with the primers for 5’CA site [Huang S, unpublished data]. The primers at both 
ends of the gene, 5’CA and MP1P, were used to detect the possible  recombination.  
3.2.3 Carrier - Testing 
DMD is an X-linked recessive disease. Female carriers were at the risk to give birth to an 
affected male infant. Performing carrier testing offered a favorable opportunity for the 
carrier to get prenatal diagnosis at the first pregnancy. For deletion/duplication mutations, 
dosage analysis can be performed with either real-time PCR or MLPA[42,43], no mater it 
was a familial case or sporadic case, even the proband deceased. For point mutation, it can 
be carried out by direct sequencing. 
For familial cases, linkage analysis can be performed[54], no mater what kind the mutation 
was. It would be offered with caution for the sporadic cases, especially the diagnosis of 
DMD was not confirmed. The markers used for linkage analysis should be highly 
polymorphic and informative, and lie both within and flanking the DMD locus[51-53].  
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The large size of the DMD gene leads to an appreciable risk of recombination. It has been 
estimated that the genetic distance was 12 centimorgans between the two ends of the 
gene[55]. Multiple recombination events may occur during meiosis and may not be detected 
when the marker was homozygous; thus, it might be aware in interpretation of the data 
generated from a linkage study.  
Males with DMD usually die before reproductive age or are too debilitated to reproduce. It 
would be convincible that there was a plenty of de novo mutations responsible for the 
sporadic cases. For sporadic cases, the proband may be resulted from: 1) the mutation 
occurred after conception and is thus present in some but not all cells of the proband's body 
(somatic mosaicism), the proband’s mother is not a carrier and the recurrence risk was very 
low; 2) germline mutation, passed from the mother. The later situation was completed, since 
the mutation could be one of the followings: a) a de novo mutation occurred in the egg, a 
meiosis mistake and the mother was normal; b) the mutation is resulted in mitosis in the 
ovary and partial of the cells carry the mutation, termed “germline mosaicism” or “gonad 
mosaicism”, the recurrence risk depends on the proportion of the mutant cell line; c) somatic 
mosaicism, the mutation presented in some but not all of the mother’s body including the 
ovary, the recurrence risk is high, up to 50%; d) a germline mutation, passed from one of 
grand-parents, or passed from ancestor on the grandmother side, the mother is the carrier. 
Put all these considerations together, carrier testing on the mother may be not informative, 
since the mutation could only be detectable in the last two situations. Since it is hard to tell 
at which level the mutations occurred, to provide carrier testing on the proband’s mother in 
the sporadic case is controversial. There might be a misleading for the family, since the 
negative result of the testing may be misunderstood even misinterpreted as the mother was 
not a carrier at all, and the prenatal diagnosis was not necessary. It would be dangerous. For 
these reasons, prenatal diagnosis must be suggested to all cases especially the mutation has 
been identified; just in case the mother had the mutant cell line. The carrier status of the 
patient’s sister can be performed if there was a detectable mutation in the proband. It should 
be aware that if the germline mutation is of the grandfather’s origin, the maternal aunts 
would be at risk for a carrier, since there was a possibility that the grandfather is of germline 
mosaicism. The origin of the mutation can be revealed with linkage analysis[54,56]. This 
information is important in genetic counseling for determining which branches of the family 
are at risk for the disease. The carrier detection can be performed with either mutation 
detection if the proband’s mutation was identified, or with linkage analysis. There is an 
ethics issue for carrier detection: the optimal time for determination of genetic risk, 
clarification of carrier status, and discussion of availability of prenatal testing, is before the 
person’s pregnancy. It is appropriate to offer genetic counseling to young adults female 
relatives who are at risk of being carriers[56]. 
3.2.4 Prenatal diagnosis 
In preventing birth of DMD fetus, prenatal test was carried out by sex selection in the early 
era, e.g., if the fetus was 46,XY, abortion would be induced. 
The first case of prenatal diagnosis was performed in 1987 in China, via pathology analysis 
of the fetus muscle biopsy taken at 20 week gestation[57]. CK measurement on amnion fluid 
was used for prenatal diagnosis of DMD before gene analysis was available[58]. This 
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approach is still used as the complementary or “rescue” procedure in prenatal diagnosis, 
when gene analysis is uninformative or linkage analysis has revealed that the fetus inherited 
the same haplotype as the proband in sporadic case. 
Prenatal diagnosis for at-risk pregnancies requires prior identification of the disease-causing 
mutation in the family. It can be offered with 50% exclusive detection if the small mutation 
detection can not be carried out. The fetal material is obtained either by chorionic villus 
sampling (CVS) at approximately ten to 12 weeks' gestation or by amniocentesis usually 
performed at approximately 15-18 weeks' gestation.  
The usual procedure in prenatal diagnosis is to determine fetal sex by PCR amplification of 
the male specific fragment, such as the ZFY gene. If the fetus is male, DNA from the fetus 
will be analyzed for the known causal mutation or tracking linkage established previously. 
If the fetus is a female, test will be stopped at this point, unless the mutation of the proband 
was identified. In this circumstance the carrier status of the female fetus might be tested. 
Prenatal testing is possible for the first pregnancy of woman in the family whose carrier 
status has been recognized by mutation detection or linkage analysis.  
The first gene diagnosis on DMD was carried out with restriction fragment length 
polymorphism (RFLP)[59]. With PCR method available, it is much easier to perform 
prenatal diagnosis for deletion cases using multiplex PCR[60,61], or with linkage analysis 
using STR markers[56,62,63], and recently MLPA method was used[56, 64].  
In our center, prenatal gene diagnosis on DMD was performed mainly with “one-step 
approach”, a linkage analysis protocol[49]. In reviewing the data of the cases analyzed with 
one-step approach since 1995, it was informative in almost all the families. After MLPA 
analysis on the remaining“non-deletion” cases screened by “one-step approach” , it revealed 
that 80% of the deletions were detected with linkage analysis [43,47]. For prenatal diagnosis, it 
was required that differentiation diagnosis and gene analysis should be performed prior to 
prenatal diagnosis with one-step approach. Since this approach can detect deletion and 
establish linkage phase simultaneously. Prenatal diagnosis was performed with the 
information collected from the pre-analysis. If it was uninformative with the linkage analysis, 
or the male fetus shared the same haplotype with the proband, or there was a chromosome 
recombination observed, MLPA analysis would be performed as a rescue procedure to see 
whether there was a deletion/duplication existed for the proband or not[56]. 
As for all X-linked genetic diseases, it should be aware that contamination with maternal DNA 
is a critical risk causing error in prenatal diagnosis. It should be incorporated the personal 
identification procedure in prenatal diagnosis. It was carried out with a set of multiplex PCR of 
unrelated markers, such as the STR markers on chromosome 21(please refer to the section of 
quality control, QC). We had the experiences that the material of CVS was from the mother 
and the amniocentesis cell grown up in the cell culture was of maternal origin. Fortunately, all 
these contamination events were revealed with the QC procedure. 
3.3 Phenylketonuria (PKU) 
3.3.1 Heterogeneity and prevalence of HPA 
Phenylketonuria (PKU) (MIM 261600), an autosomal recessive inherited metabolic disease, 
is caused by phenylalanine hydroxylase (PAH) deficiency. It was called classical PKU in 
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China before, for distinguishing it from BH4 deficiency, which was called un-classic PKU or 
malignant PKU. In China the newborn screening data showed that the incidence of 
hyperphenylalaninemia (HPA) is around 1 in 11000[65], with the highest prevalence of 1 in 
1666 in Gansu province[66]. Differentiated diagnosis was made by HPLC pterin analysis of 
the urine, measurement of RBC DHPR activity, and BH4 loading test. Classic PKU is 
diagnosed in individuals with plasma phenylalanine (Phe) concentrations higher than 1000 
μmol/L in the untreated state. PKU accounts for 80% to 94% of HPA cases in Chinese, with 
the remaining as BH4 deficiency[67]. Patients with PKU are intolerance to the dietary intake 
of phenylalanine, one of the essential amino acids. Without dietary restriction of 
phenylalanine in the early life, most children with PKU will develop irreversible profound 
intellectual disability. Newborn screening has been launched in the early of 1980’s in China 
[68]and free dietary treatment for the patients detected through the newborn screening 
program started in the early of 21 century, although the coverage of the newborn screening 
program varied from 100% in the developed area to 20% in developing areas, and no 
screening program at all in the remote areas, such as Tibetan and Qinghai province. 
3.3.2 Mutation spectrum of PAH in China 
PAH gene, located on 12q23.2, contains 13 exons and spans 90 kb, coding for a 2.4-kb mature 
mRNA. Mutation detection of the PAH gene in the PKU patients started in the late of 1987 
on Chinese patients[69]. More than 100 different mutations have been identified up to date 
in Chinese PKU patients, accounting for 94.3% of the mutant alleles [70,71]. Mutations 
observed in the PAH gene include missense, splice site, and nonsense mutations, small 
deletions, and insertions. Eight mutations, c.728G>A(p.R243Q), IVS4-1G>A(rs62514907), 
c.611A>G (p.Y204C), c.1238G>C(p.R413P), c.331C>T(p.R111X), c.1068C>A(p.Y356X), and 
c.1197A>T(pV399V), accounting for 66.2% of the mutant alleles, with the proportions of 
18.8%, 10%, 10%, 9.4%, 7%, 6%, and 5% of mutant alleles respectively [71].  
When a panel of samples was collected in a certain area, mutation scanning was carried out 
with either ASO hybridization, denaturing high-performance liquid chromatography, or 
multiple AS-PCR. In the clinical service, we use a two-step procedure to detect the 
mutations of the PAH gene. In the first step, six exons, exon 3, 5, 6, 7, 11 and 12, and their 
flanking intronic sequences were amplified by PCR and then sequenced. In a panel of the 
patients, mutations were identified in 83% of the mutant alleles in the first step. If there was 
unknown allele remained in an individual, the second step of mutation scanning was 
carried out by sequencing the other seven exons. The total detection rate was 92.3%[71].  
3.3.3 The strategy of prenatal diagnosis of PKU 
Although there has been a good newborn screening program in China for decades and 
efficient early dietary treatment was available in the country[72], there is still a demand for 
prenatal diagnosis on the second pregnancy in the family. Prenatal diagnosis of PKU may be 
controversial if the testing is for the termination of the affected fetus. But it is the alternative 
choice of the families. The reasons for the parents seeking for prenatal diagnosis are: the 
first, the cost of the dietary treatment is high, beyond the economic capacity for the families 
with an average income, although there is a free treatment in some province, and the second 
is that in the families the parents had the bit experience already in managing the first child 
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and would not want to risk the further baby bearing with the condition. It was not 
convenience in bring up the affected child and it is hard for them to make the child adhered 
to the dietary. 
The first prenatal diagnosis on PKU was performed with RFLP linkage analysis in 
1987[73]. There were other centers offering prenatal diagnosis, of which the centers at 
Peking Union Medical College[74,75] and Shanghai Xinhua Children’s Hospital[76] 
played the main roles now.  
In the beginning, linkage analysis with RFLP was tried. But unfortunately it was not as 
informative with RFLP markers as in the Caucasians, since 80% of the chromosomes were 
with haplotype 4 in Chinese [77]. Prenatal diagnosis got into service until mutation 
detection was carried out by PCR amplification and hybridized with ASO probes labeled 
with isotope [78]. The mutations of PAH gene could also be detected by methods of AS-
PCR[79], single strand conformation polymorphism(SSCP)[80], or RFLP[81] 
The limitation for all these procedures was that the two mutant alleles in the family must be 
characterized. But not in all of the cases the two mutant alleles could be identified, especially 
there was no time for detecting the mutations as the pregnant women came to clinic asking 
for prenatal diagnosis without any previous gene analysis. In addition, as more and more 
mutations being characterized in Chinese, it was hard and inconvenient for any diagnostic 
center to have all the probes ready for use. The quick procedure needed to be deveoped to 
perform prenatal diagnosis. The linkage analysis with short tandem repeats (STR), (ACAT)n 
in the intron 3 of PAH gene, emerged in 1992[82]. This marker was introduced into China in 
the same year [83]and a “quick approach” for prenatal diagnosis of PKU was proposed by 
combining this STR maker with a novel SNP (IVS3 nt-11A/C)in the PAH gene[84]. It was 
further expanded with additional STR markers incorporated. Three markers, PAH-STR, 
PAH-26 and PAH32, were used for haplotype analysis. They are highly informative and are 
both intragenic and flanking to the PAH locus. Linkage phase of mutant alleles and the 
haplotype of the markers could be established in almost all the cases[85]. For families in 
which only one PAH mutation was identified, or there is a urgent case for prenatal 
diagnosis, linkage analysis would be an option for prenatal diagnosis. But it should be kept 
in mind that the diagnosis of phenylketonuria should be confirmed (e.g. it is caused by 
mutation of phenylalanine hydroxylase gene). The shortage for using linkage strategy is that 
there is genetic heterogeneity of the HPA and not all the HPA were caused by mutation in 
PAH gene. If the differentiation diagnosis could not be made, there would be a miss 
management to treat all the cases as that caused by PAH mutation. Linkage studies are 
based on accurate clinical diagnosis of PAH deficiency in the affected family and accurate 
understanding of the genetic relationships in the family. Prenatal diagnosis should be 
applied with a caution and linkage analysis should be performed with combined with 
mutation detection. 
Different families have different story: the mutation details, the linkage phase for the STR 
markers. So, it was required for cases asking for prenatal diagnosis, that gene analysis 
should be carried out prior to being pregnant, e.g., the differentiation diagnosis, especially 
when linkage analysis was employed, and DNA typing, either mutation detection or STR 
typing. In cases that probands deceased, it was still possible to perform prenatal diagnosis 
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if the Guthrie card bloodspot was available, which might be kept in the newborn 
screening center. If differentiation diagnosis had been confirmed on the patient before 
death, linkage analysis can be done utilizing the remained genetic material. It would be 
better if mutations can be characterized using the DNA isolated from the bloodspots. The 
mutations in the family could be also identified by sequencing the parents’ DNAs if the 
proband’s DNA was not available, although the procedure was rather complicated in 
confirming the causal mutation. 
3.4 Spinal muscular atrophy (SMA) 
3.4.1 Molecular genetics of SMA  
Spinal muscular atrophy (SMA) is characterized by progressive muscle weakness resulting 
from degeneration and loss of the anterior horn cells in the spinal cord and the brain stem 
nuclei. Onset ranges from before birth to adolescence or young adulthood. 
Electromyography (EMG) reveals denervation and diminished motor action potential 
amplitude. 
SMA was classified into clinical subtypes according to the onset age and maximum function 
achieved. Infants of SMA 0, with prenatal onset and severe joint contractures, facial diplegia, 
and respiratory failure, died soon after birth. Children with SMA I (Werdnig-Hoffmann 
disease) manifest weakness before age six months and never be able to sit independently. 
The life expectancy for SMA I patients is less than two years. For SMA II (Dubowitz 
disease), with onset between age six and 12 months, the life expectancy is not known with 
certainty, some live into adolescence or as late as the third or fourth decade. The individuals 
with SMA III (Kugelberg-Welander disease) clinically manifest their weakness after age 12 
months and are able to walk independently. SMA IV is the adult onset type.  
SMA is inherited in an autosomal recessive manner. Two genes were considered related to 
SMA, SMN1 (survival motor neuron 1) and SMN2, which locate on 5q12.2-q13.3 head to 
head with SMN1. SMN1 is the primary disease-causing gene. Most people have one copy of 
SMN1 on each chromosome, and there are about 4% of the chromosomes have two copies of 
SMN1. The number of SMN2 copies ranges from zero to five in normal individuals, while 
there is at least one copy of SMN2 remains in SMA patients. SMN1 and SMN2 differ by five 
single base-pair, locate in introns 6(g/a) and 7(a/g and a/g), and exons 7(C/T) and 8(G/A). 
The C/T SNP at position 6 of exon 7 is critical, since this change causes skipping of exon 7 in 
the mRNA of SMN2 resulted in loss the function of SMN2, while the difference in exon 8 is a 
SNP in the 3’UTR of the genes. 
About 95%-98% of individuals with SMA are homozygous deletion and about 2%-5% are 
compound heterozygotes for an SMN1 deletion and an intragenic SMN1 mutation. Some of 
the deletion of SMN1 is caused by conversion between SMN1 and SMN2, with the 3’ portion 
of SMN2, not actually a real deletion.  
3.4.2 Advantages in genetic testing  
Prenatal gene diagnosis was carried out in China mainly on homozygous deletion cases, 
typically determined by lack of exon 7 of SMN1. Since there is at least on copy of SMN2 
remains in the SMA patients, Methods developed for deletion detection attempting to avoid 
www.intechopen.com
 
The Experiences of Prenatal Diagnosis in China 
 
183 
amplification of the SMN2 gene. In the beginning diagnosis of homozygous deletion of 
SMN1 was carried out by SSCP analysis [86]. Since the pattern of the SSCP bands was rather 
complicated, a PCR-RFLP protocol was then adapted to replace SSCP procedure[87]. The 
difference at position 6 of exons 7 between SMN1 and SMN2 was considered for primer 
design. An artificial restriction site of Dra I (TTTAAA) was created by introducing a 
mismatched T in the primer. The exons 7 of both SMN genes were amplified and the PCR 
products were cut with Dra I. Since the products of SMN2 has the restriction site while 
SMN1 fragment doesn’t, there would be no band corresponding to SMN1 and only a smaller 
band for SMN2 remained in homozygous deletion patients. For the PCR-RFLP procedure, 
there is a shortage of uncompleted digestion of the SMN2 fragment, which would be 
misinterpreted as the present of normal SMN1 copy. It was dangerous when it occurred in 
prenatal diagnosis. Other methods were investigated to overcome this limitation, such as 
DHPLC and MLPA to detect the copy numbers of SMNs[88]. For the purpose for detection 
of homozygous deletion, a more simplified approach was developed. SMNl gene was 
amplified specifically with double allele-specific PCR(AS-PCR)( e. g. both primers for SMN1 
amplification were SMN1 specific, utilizing SNPs at exon 7 and intron 7), coupled with a 
pair of primers for an irrelevant gene as internal control[89]. The products were separated 
by agarose gel electrophoresis or PAGE to determine whether the patients were of 
homozygous deletion of SMN1 gene. Comparing to PCR-RFLP and DHPLC used in the 
past, this approach can diagnose homozygous deletion of SMN1 much more accurate, easier 
and more convenient without the interference of SMN2.This approach could be further 
modified by keeping the PCR cycles by 25 and quantitatively determining the density of the 
bands by densitometer, or using fluorescent labeling primer for quantitative PCR.  
3.4.3 The feasibility of prenatal diagnosis for first pregnancy at risk for SMA 
With all the progress, it is possible to perform prenatal diagnosis for the family in which the 
proband deceased, the same story as in PKU. Deletion detection could be performed by 
dosage analysis if there were tissue samples available from the proband, such as bloodspots 
from newborn screening. If there is no DNA available, SMN1 dosage analysis may be 
performed on both parents to see if they were both with only one copy of SMN1. It is much 
easier to confirm the carrier status for the parents with real-time PCR or MLPA. But there 
might be a blind corner when the patient was a compound heterozygote or one of the 
parents has two SMN1 copies on one chromosome when dosage analysis was performed. 
It is reasonable to offer prenatal diagnosis for these family as a 50% exclusive diagnosis, in 
hope that the deceased proband was really homozygous deletion no mater that one of 
his/her parents had two copies of SMN1on one chromosome or he/she was resulted in a 
de novo mutation of deletion. In case of intragenic mutation, the mutation might be 
revealed by sequencing the SMN1 gene of the parent with two copies of SMN1. It is also 
feasible to detect carrier of deletion mutation in the population using this approach, at 
least for the relatives of the patient and his/her spouse. It was proposed to carry out 
population screening with the double AS-PCR procedure, since the rate of the carrier with 
deletion type was as high as 1 in 50[89]. It will make the prenatal diagnosis possible on 
the first pregnancy for the couples both with a single copy of SMN1, as doing on 
thalassemias in Southern China.  
It may be further increase the chance of prenatal diagnosis for the patients of non-
homozygous deletion by screening the possible intragenic mutation by sequence SMN1 
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gene of the patient. But it should be offered with caution since the heterozygote frequency of 
SMN1 deletion is as high as 1 in 50, the diagnosis of SMA must be confirmed. For 
sequencing the SMN1 gene, it can be achieved by a method that facilitates SMN1-specific 
amplification. Since there were more copies of SMN2 than SMN1 at DNA level, and only 
15% of the SMN2 mRNA was full length (fl-mRNA), it may be easier to reveal the mutation 
by cDNA sequencing approach. Sequencing the full length mRNA of SMNs will increase the 
signal of the mutant allele since the ratio of fl-mRNA of SMN2 to that of SMN1 was reduced 
at the mRNA level. It has additional strength with cDNA sequencing strategy. The 
mutations affecting mRNA processing would be revealed much easier, no mater how deep 
it was hided within the intron. It will be able to detect the mutation responsible for 
transcription regulation if quantitative analysis of SMN1 mRNA was performed. There is 
also an alternative approach for characterizing the intragenic mutation, e.g., by long-range 
PCR protocol and subcloning. 
3.4.4 Be ware of contamination 
Prenatal diagnosis of SMA was relied on deletion detection. If there was no amplification 
the fetus would be considered as affected. It would be dangerous when contamination of 
maternal material occurred. The amplification of SMN1 exon 7 might be from the maternal 
DNA, since the mother had a normal SMN1 allele. To rule out the contamination of 
maternal material linkage analysis was performed routinely with STR markers on 
chromosome 21(section of quality control for prenatal diagnosis).  
3.5 Personalized service in rare disease 
Prenatal diagnosis was also offered to families with other genetic diseases as personalized 
services. In this case, mutation detection should be carried out in advance. There were more 
than 40 diseases available for this service in our center and more than 70 diseases were 
offered in other prenatal diagnosis center or department of medical genetics.  
4. Quality control on the prenatal diagnosis 
4.1 Be ware of heterogeneity 
In practice of prenatal diagnosis the accuracy is very important. Since there is heterogeneity 
for genetic diseases, it was critical to confirm the diagnosis of the disease in the family 
seeking prenatal diagnosis.  
4.2 Using different procedures to confirmed the output 
It would be helpful to use two different protocols to carry out prenatal diagnosis, mutation 
detection and linkage analysis. For deletion analysis, in addition to use internal control 
linkage analysis should be used, which can tell if there was a contamination occurred. 
4.3 Emphasis on pre-analysis in advance to prenatal diagnosis 
It is always happened that the pregnant women come for prenatal diagnosis at high 
gestation weeks without confirmation diagnosis of the proband or with no previous gene 
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analysis. Without genetic analysis in advance, it would be not sure if the prenatal diagnosis 
can be performed, since it might be uninformative with the commonly used polymorphic 
markers, or the mutations in the family can not be identified.  
4.4 Ensure the fetal material is really from fetus 
The maternal contamination was a serious risk, esprcially for deletion mutation. The mother 
always carried a normal allele which will give a positive amplification. We put an emphasis 
on sampling and sample processing: 1)CVS would be the first choice to get fetus material in 
our practice. When the sample received the chorionic villus would be carefully selected. 2)If 
amnion fluid had to be used the sample should be check for sure there was no blood 
contaminated. It can be told by sitting the fluid for a half hour to see if there was red cells 
precipitated. If it is so, cell culture will be set up. To avoid omission of the contamination, 
linkage analysis should be performed paralleling with mutation detection.  
4.4.1 Get three birds with one stone 
In our practice we performed linkage analysis first using two STRs on chromosome 21. By 
this procedure, we can get three answers: 1) whether the fetus was at risk for trisomy 21. If 
there is three alleles for the fetus or there were just two alleles but the density of one allele 
was nearly doubled, the fetus was affected with trisomy 21. Since we detected 2 markers, the 
chance for there was only one band, e. g. the parents were homozygous for two markers, 
was rare; 2) whether the fetal sample was taken from the fetus tissue. If the alleles were the 
same as the maternal ones and there is no paternal allele, it implied that the sample was not 
from the fetus but of maternal origin. It also showed whether there was a contamination 
with the maternal material, if there was an extra allele passed form the mother, and the 
density of the extra band was much weaker; 3) was the sample misplaced, if the genotypes 
of the parents and fetus were not matched.  
In our practice we have confronted with the situation 2, there were maternal contamination 
and even worse that the sample was taken from the mother, not from the fetus. To confirm 
the later situation, more marker, other than markers on chromosome 21, were used for 
personal identification as doing in paternity testing. We called this procedure as “get three 
birds with one stone”. If it implied the possibility for trisomy 21, markers on other 
chromosome would be tested. If there was no extra allele for the new markers, trisomy 21 
was suspected, and AF sampling would be suggested in order to rule out the confined 
trisomy 21 in the CVS. If there was maternal contamination, fetus sample should be 
collected again. If there was a trouble in sample preparation, DNA would be extracted from 
the back up material, which was reserved in the original sample tube. If the polymorphic 
marker didn’t give sufficient information, dosage analysis could be help. In our practice the 
contaminating band was always with a lower density, much less than 1 copy.  
4.4.2 Be aware of the maternal origin of the grown cells from AF culture 
When contamination of the maternal blood was suspected on AF sample, the routine way to 
get ride of the maternal white blood cells is to culture the amnion fluid cells. After several 
changes of the medium the blood cells would be washed away, leave the fetal cells grow up 
as fibroblast cells adhering on the culture flask. But in our practice in one case it turned to be 
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that the grown cells were maternal origin since all the markers tested gave the same 
genotype as the mother’s DNA did. Considering this situation, we added the STR testing 
procedure to all the prenatal diagnosis for monogenic diseases, such as for enzyme assay.  
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